LENZ Therapeutics, Inc. - Common Stock LENZ 深 滬
已收盤 08-01 16:00:00 美东时间
29.96
+0.190
+0.64%
華盛通- 最 高31.59
- 今 開30.01
- 成交量 156.94万股
- 最 低 29.00
- 昨 收 29.77
- 總市值 8.43亿
- 52周最高 38.93
- 市盈率 靜 --
- 換手率 5.58%
- 52周最低 16.535
- 委 比 11.31%
- 總股本 2814.62万
- 歷史最高 230.79
- 量 比 5.20
- 振 幅 8.70%
- 歷史最低 3.92
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 罕见！Meta、微软连续获多家大行上调目标价；花旗上调Robinhood目标价升至120美元
今日重点评级关注：丰业银行：维持Arcellx"跑赢大市"评级，目标价从93美元升至133美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从89美元升至100美元
08-01 10:17
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
VIZZ, the first FDA-approved aceclidine-based eye drop for treating presbyopia, improves near vision for up to 10 hours with once-daily use. LENZ Therapeutics announced its approval, with samples expected in the U.S. as early as October 2025 and broader availability by mid-Q4 2025. VIZZ's unique mechanism contracts the iris sphincter, creating a pinhole effect without myopic shift. Clinical trials demonstrated significant near vision improvement ...
07-31 20:05
Lenz Therapeutics Prepares for LNZ100 Launch
Lenz Therapeutics, Inc. ( ($LENZ) ) has released its Q2 earnings. Here is a bre...
07-31 14:53
LENZ Therapeutics Q2 EPS $(0.53) Beats $(0.62) Estimate, Sales $5.000M Beat $4.181M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.62) by 14.52 percent. This is a 32.5 percent decrease over losses of $(0.40) per share from
07-30 20:11
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported its NDA for LNZ100, an aceclidine-based eye drop for presbyopia, remains on track for an August 8, 2025 PDUFA decision. The company has hired an 88-member sales force and secured over $195 million in upfront and milestone payments through international licensing agreements. Cash reserves of $209.6 million as of June 30, 2025 are expected to support operations to post-launch profitability.
07-30 12:00
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Raises Price Target to $48
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $38 to $48.
07-28 18:15
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
CORXEL Pharmaceuticals submitted LNZ100's NDA to China's NMPA, marking the first milestone under LENZ's collaboration agreement. The Phase 3 trial in China showed significant improvements in near vision, supporting this regulatory milestone. LENZ is eligible for up to $95 million in milestones and royalties. This submission, the first outside the U.S., highlights LNZ100's potential as a global presbyopia therapy.
07-28 12:00
LENZ Therapeutics And Laboratoires Théa Announce Exclusive License And Commercialization Agreement For Théa To Register, Commercialize LNZ100 For Presbyopia Treatment In Canada
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Laboratoires Théa ("Théa") announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada.
07-07 20:05
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
LENZ Therapeutics and Théa have signed an exclusive agreement for the registration and commercialization of LNZ100 in Canada for presbyopia treatment. LENZ will receive over $70 million in payments and royalties, while Théa gains exclusive rights. This partnership highlights Théa's strong position in eye care and LENZ's focus on expanding global access to its innovative therapy.
07-07 12:00
LENZ Therapeutics Prepares for LNZ100 Launch
Lenz Therapeutics, Inc. ( ($LENZ) ) has released its Q1 earnings. Here is a bre...
05-31 11:54
